Budde Ulrich, Pieconka Antje, Will Kirsten, Schneppenheim Reinhard
Coagulation Laboratory, Laboratory Association Professor Arndt and Partners, Hamburg, Germany.
Semin Thromb Hemost. 2006 Jul;32(5):514-21. doi: 10.1055/s-2006-947866.
The stepwise diagnosis of von Willebrand disease (vWD) includes patient and family history, screening procedures (bleeding time, filter tests, platelet counts, activated partial thromboplastin time [aPTT]), confirmatory tests (von Willebrand factor [vWF]:antigen [Ag], vWF:ristocetin cofactor activity assay [RCo], vWF:collagen-binding test [CB], ristocetin-induced platelet agglutination [RIPA], and factor [F] VIII:coagulant activity [C]) and tests for final classification (multimeric analysis, vWF:factor VIII binding, and platelet vWF). Accumulating knowledge of the different clinical phenotypes and the pathophysiological basis of the disease have been translated into a classification that differentiates between quantitative and qualitative defects by means of quantitative and functional parameters and by analyzing the electrophoretic pattern of vWF multimers, but without inclusion of the genotype. Recently, it has been shown that with a sensitive method of multimer analysis, a > 90% genotype-phenotype relation may be achieved in the near future.
血管性血友病(vWD)的逐步诊断包括患者及家族史、筛查程序(出血时间、筛选试验、血小板计数、活化部分凝血活酶时间[aPTT])、确诊试验(血管性血友病因子[vWF]:抗原[Ag]、vWF:瑞斯托霉素辅因子活性测定[RCo]、vWF:胶原结合试验[CB]、瑞斯托霉素诱导的血小板凝集[RIPA]以及因子[F]VIII:凝血活性[C])和最终分类试验(多聚体分析、vWF:因子VIII结合以及血小板vWF)。对该疾病不同临床表型和病理生理基础的认识不断积累,已转化为一种分类方法,该方法通过定量和功能参数以及分析vWF多聚体的电泳图谱来区分数量和质量缺陷,但不包括基因型。最近有研究表明,采用一种敏感的多聚体分析方法,在不久的将来可能实现>90%的基因型-表型关联。